Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group.
To determine the frequency of positive human immunodeficiency virus (HIV) serostatus among North American women 50 years of age or younger with invasive cervical cancer and to define their tolerance to treatment. Consenting patients with newly diagnosed invasive cervical cancer, age 50 or younger were tested by enzyme-linked immunosorbent assay. The study design anticipated that approximately 3% of patients would be HIV positive. After the accrual of 913 eligible and evaluable patients, interim analysis revealed that only 9/913 ( approximately 1%) patients were HIV seropositive, indicating that it would not be feasible to achieve the study objective. The study was closed to further accrual. Between 1994 and 1997, the frequency of positive HIV serostatus among North American women with newly diagnosed cervical cancer was quite low. As a consequence, no evaluation of response to treatment or treatment tolerance can be made.
Calkins
A
A
Radiation Oncology, St. Joseph's Hospital/Cancer Institute, Fred J. Woods Radiation Center, Tampa, Florida, USA.
Stehman
F B
FB
Bundy
B
B
Benda
J A
JA
Mannel
R S
RS
Seago
P
P
Cappuccini
F
F
Alvarez
R D
RD
Monk
B J
BJ
Maiman
M
M